Abstract：Objective: To improve the diagnosis and treatment of chromophobe renal cell carcinoma (CRCC), we investigated the clinical features of CRCC patients in our hospital. Methods: We retrospectively reviewed the clinicopathologic data of 76 patients with CRCC seen in our hospital from January 2010 to July 2013. The mean age of these patients at diagnosis was 49 years-old, including 40 males and 36 females. All tumors were localized unilaterally, with 37 in left kidney and 39 in right kidney. Results: All of the 76 patients successfully received nephrectomy. Forty-seven patients underwent radical nephrectomy, 29 patients received nephron sparing surgery. Seventy-three patients were treated with laparoscopic surgery and 3 were treated with open surgery, with the similar mean operative time. The mean operative blood loss was significantly less in laparoscopic surgery group. The average maximum diameter of tumors was 4.6 cm. Among them, 64 patients were at pT1N0M0, 10 at pT2N0M0, 1 at pT3N0M0and 1 at pT1N0M1. The pathologic Fuhrman grade of CRCC was G1 in 50 cases, G2 in 16 cases, G3 in 6 cases, G4 in 4 cases. All patients were followed up with a mean duration of 33.8 months and no local recurrence was found. Conclusions: CRCC is a rare subtype of renal cell carcinoma with infrequent recurrence and metastasis. Surgery is the standard treatment for CRCC. The laparoscopic surgery has similar treatment efficacy to open surgery, but deserves significant micro-invasive advantages. CRCC patients have favorable prognosis.
[1]Cheville JC, Lohse CM, Sukov WR, et al. Chromophobe renal cell carcinoma:the impact of tumor grade on outcome. Am J Surg Pathol, 2012,36(6):851-856.
[2]Thoenes W, Storkel S, Rumpelt HJ. Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol, 1985, 48 (3) :207-217.
[3]Cindolo L, de la Taille A, Schips L, et al. Chromophobe renal cell carcinoma:comprehensive analysis of 104 cases from multicenter European database. Urology, 2005, 65 (4) :681-686.
[4]Paner GP, Amin MB, Alvarado-Cabrero I, et al. A novel tumor grading scheme for chromophobe renal cell carcinoma:prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol, 2010, 34 (9) :1233-1240.
[5]Larkin JM, Fisher RA, Pickering LM, et al. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus. J Clin Oncol, 2011, 29 (9) :e241-242.
[6]Volpe A, Novara G, Antonelli A, et al. Chromophobe renal cell carcinoma (RCC):oncological outcomes and prognostic factors in a large multicentre series. BJU Int, 2012, 110 (1) :76-83.
[7]Kim JK, Kim TK, Ahn HJ, et al. Differentiation of subtypes of renal cell carcinoma on helical CT scans. AJR Am J Roentgenol, 2002, 178 (6) :1499-1506.
[8]Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol, 2004, 11 (1) :71-77.
[9]Amin MB, Paner GP, Alvarado-Cabrero I, et al. Chromophobe renal cell carcinoma:histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol, 2008, 32 (12) :1822-1834.
[10]Mazal PR, Exner M, Haitel A, et al. Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma. Hum Pathol, 2005, 36 (1) :22-28.
[11]Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol, 2008, 26 (1) :127-131.
[12]Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol, 2009, 26 (2) :202-209.
[13]Zini L, Leroy X, Lemaitre L, et al. Tumour necrosis in chromophobe renal cell carcinoma:clinical data to distinguish aggressive variants. Eur J Surg Oncol, 2008, 34 (6) :687-691.
